“By the way, I’m not a hydroxychloroquine doctor. I’m a zinc ionophore doctor. All the data show that if you increase intercellular zinc enough it will inhibit RNA virus replication. … You need a transport mechanism to get zinc from outside the cell to inside the cell.” Quote of Dr. Zelenko taken from this interview, September 2nd, 2021. 15:35 mark.
Now let’s look at the CETF-funded hydroxychloroquine trial.
From MIT Technology Review, October 10, 2021. First, I have to point this out before we get into the study. Did you know that Rockefeller Philanthropy advisors are not related to the Rockefeller Foundation, according to MIT Technology Review, which is funded by the Rockefeller Foundation? That’s what MIT says. Kirsch is an MIT alum.
(The (CETF) fund borrows its nonprofit status from the 501(c)(3) Rockefeller Philanthropy Advisors, which managed its money until it quit, according to the Daily Beast; neither organization is related to the Rockefeller Foundation, which supports Technology Review's reporting on covid.)
So Kirsch and MIT Tech Review are associated with the Rockefellers, but the Rockefeller orgs aren’t associated with each other. Got that? OK great, moving on to the CEFT hydroxychloroquine study, as reported by the Rockefeller Foundation, I mean MIT Tech Review.
One of the first CETF grants was to investigate the antimalarial hydroxychloroquine. David Boulware, a researcher at the University of Minnesota, received $125,000 to test the drug against covid.
David Boulware began enrolling participants in his trial on March 17, 2020: This is a link to his study: A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Participants had known exposure (by participant report) to a person with laboratory-confirmed Covid-19…. Trial enrollment began on March 17, 2020, with an eligibility threshold to enroll within 3 days after exposure…
What’s going on back in March 2020? All hell was breaking loose, that’s what.
On March 20, 2020, President Trump was in a press conference with Anthony Fauci where Fauci said the following:
Anthony Fauci: “The evidence you’re talking about John is anecdotal evidence. So as the Commissioner of FDA and President mentioned yesterday, we’re trying to strike a balance between making something with a potential of an effect to the American people available and at the same time we do it under the auspices of a protocol that would give us information to determine it it’s truly safe and truly effective.”
On March 21, 2020, Dr. Zelenko made a video address to President Trump, where he said that HCQ needed to be allocated to the public as a preventative measure.
“What I’m suggesting, which has not yet been suggested, that’s why I’m making this video, is that we should initiate treatment in moderate to high risk patients in the early stages of an infection, in an outpatient setting.”
On March 28, 2020, the FDA issued an Emergency Use Authorization for hydroxychloroquine, but there was a huge problem: it was only authorized for use in patients who were already hospitalized, against the recommendation of Dr. Zelenko.
That same day March 28, 2020, Tech Startups reported that Dr. Zelenko had successfully treated 699 COVID patients with “hydroxychloroquine, in combination with azithromycin (Z-Pak), an antibiotic to treat secondary infections, and zinc sulfate.”
So by this point Dr. Zelenko’s Z-I-N-C ionophores protocols and 100% success rates were public.
Dr. Zelenko said the whole treatment costs only $20 over a period of 5 days with 100% success.
President Trump announced on May 18, 2020, that he was taking hydroxychloroquine.
The next day, May 19, 2020, CNN broke the glass on CETF-funded Dr. David Boulware to push back against Trump’s announcement that he was taking hydroxychloroquine as a preventative measure based on Dr. Zev Zelenko’s advice.
CETF-funded Dr. David Boulware told CNN: (screenshot)
Erin Burnett: And I know, doctor, there hasn’t been much research done on using hydroxychloroquine basically to prevent someone from getting coronavirus if you’re exposed to it, and they want to make sure you don’t get it: taking hydroxychloroquine in that capacity, which is what the President appears to be doing. He says he started taking it about 10 days ago, which is around the time when his personal valet tested positive. You are researching the drugs use in that capacity. I know the White House did reach out to you to ask for your advice. What happened?
Dr. Boulware: Well I think the issue of can hydroxychloroquine be used as a preventative is really unknown and so that’s why we’re doing the clinical trials to try to answer that question. So at this stage it might work; it might not work, and so we really don’t know. And so the recommendation for the general public is that this is not a medicine to be used outside a clinical trial or if you’re hospitalized where you can be monitored closely. And that’s really what the FDA has said before.
Dr. Boulware agreed with with Fauci that hydroxychloroquine should only be used in hospitals and clinical trials. CETF-funded Dr. Boulware was of course conducting his own trial, and wasn’t exactly optimistic about the potential for success: “it might work, it might not work.”
When Boulware et al published their results, they said it didn’t have a benefit.
CONCLUSIONS
After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure.
PRIMARY OUTCOME
The incidence of new illness compatible with Covid-19 did not differ significantly between those receiving hydroxychloroquine (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]) (P=0.35). The absolute difference was −2.4 percentage points (95% confidence interval, −7.0 to 2.2). Figure 2 shows the development of Covid-19 over time. Two hospitalizations were reported (one in each group). No arrhythmias or deaths occurred.
Some people will look at that last paragraph and ask just what was the big deal about “COVID” anyway, considering that there were only two hospitalizations and zero deaths, and that 407 patients received “not a damn thing” (placebo), which just goes to prove that the COVID Plandemic was faked with Remdesivir/Ventilator/Opioid murders, but that’s another story. Anyway, the CETF-funded story served to further the narrative that their was no cure for a novel and deadly pathogen, until later when the FDA approved the real killer that murderous hospitals were already using under some “compassionate use” nonsense without an EUA - Remdesivir. You won’t hear that from Steve Kirsch. But this was study was done by mailing the products to household, so the people were at home where the hospitals couldn’t kill them.
A few months ago (date of publication Oct 5, 2021), Kirsch suddenly stopped promoting hydroxychloroquine—even scrubbing it from the CETF’s official list of trials it has funded. He wrote on his personal website that he’d been advised that being associated with the drug “would immediately trash my credibility.”
Regarding his credibility, first of all, why is it that I can say the hospitals were killing patients, but he can’t? I would also like to know where was the zinc in the CETF-funded hydroxychloroquine trial used to prove that HCQ could not stop transmission of the mystery virus that only kills hospitalized patients? If that study used zinc, they didn’t mention it.
Hydroxychloroquine sulfate or placebo was dispensed and shipped overnight to participants by commercial courier. The dosing regimen for hydroxychloroquine was 800 mg (4 tablets) once, then 600 mg (3 tablets) 6 to 8 hours later, then 600 mg (3 tablets) daily for 4 more days for a total course of 5 days (19 tablets total).
Did you not listen to what Dr. Zelenko was saying at all about how zinc ionophores stopped RNA viruses from replicating? I think you owe the public an explanation. I’m sure Dr. Zelenko would agree.
Charles Wright